ZYBT1   Click here for help

GtoPdb Ligand ID: 11193

Synonyms: example 13 [WO2015132799A2]
Compound class: Synthetic organic
Comment: ZYBT1 is reported as a potent and irreversible Bruton's tyrosine kinase (BTK) inhibitor [1-2]. It is able to inhibit the ibrutinib-resistant BTKC481S mutant. ZYBT1 mediates anti-inflammatory activity in models of rheumatoid arthritis and has antiproliferative action against B-cell lymphoma xenograft tumours [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 131.92
Molecular weight 494.22
XLogP 3.33
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C=CC(=O)N1CC2C(C1)CC(C2)n1nc(c2c1ncnc2N)c1ccc(cc1)C(=O)Nc1ccccn1
Isomeric SMILES C=CC(=O)N1CC2C(C1)CC(C2)n1nc(c2c1ncnc2N)c1ccc(cc1)C(=O)Nc1ccccn1
InChI InChI=1S/C27H26N8O2/c1-2-22(36)34-13-18-11-20(12-19(18)14-34)35-26-23(25(28)30-15-31-26)24(33-35)16-6-8-17(9-7-16)27(37)32-21-5-3-4-10-29-21/h2-10,15,18-20H,1,11-14H2,(H2,28,30,31)(H,29,32,37)
1. Desai RC, Bahekar R, Patel D, Shah K. (2015)
Novel heterocyclic compounds.
Patent number: WO2015132799A2. Assignee: Cadila Healthcare Limited. Priority date: 03/02/2014. Publication date: 11/09/2015.
2. Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, Sharma M, Singh J, Mohapatra J, Chatterjee A et al.. (2020)
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
Pharmacol Res Perspect, 8 (4): e00565. [PMID:32790160]